Treatment with GLP-1 agonists reduces food intake and hunger, promoting fullness and satiety with the ultimate result of weight loss in patients with obesity or type 2 diabetes13,83,84. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.